Key Points
- Director Gregory Lucier bought 22,445 shares at an average $14.03 on March 3 for $314,903.35, raising his stake to about 50,000 shares (an 81.46% increase), a notable insider purchase that can signal management confidence.
- DENTSPLY SIRONA reported $0.27 EPS (missing estimates by $0.01) and $961M in revenue (+6.2% YoY) and set FY2026 guidance of 1.40–1.50 EPS, while analysts forecast roughly 1.84 EPS for the current year.
- The stock carries a 4.8% dividend yield and mixed analyst sentiment—an average "Hold" rating with a $14.42 price target, though some firms (including Barrington and Bank of America) have recently raised targets or upgraded the shares.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) Director Gregory Lucier purchased 22,445 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were purchased at an average price of $14.03 per share, for a total transaction of $314,903.35. Following the completion of the purchase, the director directly owned 50,000 shares of the company's stock, valued at approximately $701,500. This trade represents a 81.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
DENTSPLY SIRONA Price Performance
Shares of XRAY stock opened at $13.30 on Wednesday. DENTSPLY SIRONA Inc. has a 12 month low of $9.85 and a 12 month high of $17.18. The company has a market capitalization of $2.66 billion, a P/E ratio of -4.43, a P/E/G ratio of 1.68 and a beta of 0.97. The stock has a 50 day moving average of $12.52 and a two-hundred day moving average of $12.47. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.
DENTSPLY SIRONA Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were paid a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.8%. DENTSPLY SIRONA's dividend payout ratio is currently -21.33%.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. Mizuho increased their price target on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Monday. Wells Fargo & Company upped their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an "equal weight" rating in a research note on Friday, February 27th. Zacks Research upgraded DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a research report on Monday. UBS Group decreased their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, February 3rd. Finally, Bank of America upgraded DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Three analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, DENTSPLY SIRONA currently has an average rating of "Hold" and an average price target of $14.42.
Check Out Our Latest Research Report on DENTSPLY SIRONA
Hedge Funds Weigh In On DENTSPLY SIRONA
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock valued at $211,470,000 after acquiring an additional 6,970,086 shares during the last quarter. Armistice Capital LLC grew its holdings in DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock valued at $72,790,000 after purchasing an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier's stock valued at $58,480,000 after purchasing an additional 4,003,606 shares in the last quarter. Norges Bank acquired a new stake in DENTSPLY SIRONA in the second quarter worth $39,700,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock worth $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Institutional investors own 95.70% of the company's stock.
More DENTSPLY SIRONA News
Here are the key news stories impacting DENTSPLY SIRONA this week:
- Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
- Positive Sentiment: Barrington Research raised its price target to $17 and maintained an "outperform" rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
- Neutral Sentiment: Mizuho raised its price target to $16 but kept a "neutral" rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
- Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
- Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
- Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
- Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)
About DENTSPLY SIRONA
(
Get Free Report)
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
